glucagon (1-6): has lipolytic & adenyl cyclase stimulating activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 194323 |
CHEMBL ID | 749 |
SCHEMBL ID | 18642431 |
MeSH ID | M0110686 |
Synonym |
---|
69658-84-0 |
gtpl1147 |
glucagon 1-6 |
glucagon-(1-6) |
(2s)-2-[[(2s,3r)-2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-amino-3-(3h-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoic acid |
glucagon (1-6) |
CHEMBL749 |
l-phenylalanine, n-(n-(n-(n2-(n-l-histidyl-l-seryl)-l-glutaminyl)glycyl)-l-threonyl)- |
SCHEMBL18642431 |
his-ser-gln-gly-thr-phe |
n-[14-amino-1,4,7,10,13-pentahydroxy-2-(1-hydroxyethyl)-8-(3-hydroxy-3-iminopropyl)-11-(hydroxymethyl)-15-(1h-imidazol-5-yl)-3,6,9,12-tetraazapentadeca-3,6,9,12-tetraen-1-ylidene]phenylalanine |
DTXSID80989783 |
Q27077816 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1346014 | Rat glucagon receptor (Glucagon receptor family) | 1979 | The Journal of biological chemistry, Jan-25, Volume: 254, Issue:2 | Glucagon1-6 binds to the glucagon receptor and activates hepatic adenylate cyclase. |
AID73752 | Relative binding was evaluated by measuring competition for glucagon receptor between [1-6]glucagon and the compound. | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Development of potent truncated glucagon antagonists. |
AID34457 | Relative potency was evaluated by measuring potency for conversion of [alpha-32P]ATP to cyclic 3',5'-AMP relative to glucagon | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9 | Development of potent truncated glucagon antagonists. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.42) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |